191 related articles for article (PubMed ID: 12113061)
21. Cancer-related cachexia and oxidative stress: beyond current therapeutic options.
Mantovani G; Macciò A; Madeddu C; Massa E
Expert Rev Anticancer Ther; 2003 Jun; 3(3):381-92. PubMed ID: 12820780
[TBL] [Abstract][Full Text] [Related]
22. Cytokines and cancer anorexia cachexia syndrome.
Bennani-Baiti N; Davis MP
Am J Hosp Palliat Care; 2008; 25(5):407-11. PubMed ID: 18403577
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of cancer cachexia: new insights into an old problem.
Muscaritoli M; Bossola M; Aversa Z; Bellantone R; Rossi Fanelli F
Eur J Cancer; 2006 Jan; 42(1):31-41. PubMed ID: 16314085
[TBL] [Abstract][Full Text] [Related]
24. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
Graves E; Hitt A; Pariza MW; Cook ME; McCarthy DO
Res Nurs Health; 2005 Feb; 28(1):48-55. PubMed ID: 15625711
[TBL] [Abstract][Full Text] [Related]
25. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients.
Fortunati N; Manti R; Birocco N; Pugliese M; Brignardello E; Ciuffreda L; Catalano MG; Aragno M; Boccuzzi G
Oncol Rep; 2007 Dec; 18(6):1521-7. PubMed ID: 17982639
[TBL] [Abstract][Full Text] [Related]
26. [Role of NF-kappa B in cancer cachexia].
Zhou W; Jiang ZW; Jiang J; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):683-6. PubMed ID: 15329260
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
[TBL] [Abstract][Full Text] [Related]
28. Current pharmacological management of anorexia in cancer patients.
Bruera E
Oncology (Williston Park); 1992 Jan; 6(1):125-30; discussion 132, 137. PubMed ID: 1531597
[TBL] [Abstract][Full Text] [Related]
29. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future.
Argilés JM; Busquets S; García-Martínez C; López-Soriano FJ
Nutrition; 2005 Sep; 21(9):977-85. PubMed ID: 16043325
[TBL] [Abstract][Full Text] [Related]
30. [Molecular mechanisms of cancer cachexia].
Lelbach A; Muzes G; Feheŕ J
Orv Hetil; 2004 Nov; 145(46):2329-34. PubMed ID: 16106904
[TBL] [Abstract][Full Text] [Related]
31. Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia.
Wang W; Andersson M; Lönnroth C; Svanberg E; Lundholm K
J Exp Clin Cancer Res; 2005 Mar; 24(1):99-107. PubMed ID: 15943039
[TBL] [Abstract][Full Text] [Related]
32. Emergence of ghrelin as a treatment for cachexia syndromes.
DeBoer MD
Nutrition; 2008 Sep; 24(9):806-14. PubMed ID: 18725076
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress and wasting in cancer.
Laviano A; Meguid MM; Preziosa I; Rossi Fanelli F
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):449-56. PubMed ID: 17563463
[TBL] [Abstract][Full Text] [Related]
34. On our way to targeted therapy for cachexia in cancer?
Boddaert MS; Gerritsen WR; Pinedo HM
Curr Opin Oncol; 2006 Jul; 18(4):335-40. PubMed ID: 16721127
[TBL] [Abstract][Full Text] [Related]
35. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of cachexia on survival and outcome of cancer patients.
Dimitriu C; Martignoni ME; Bachmann J; Fröhlich B; Tintărescu G; Buliga T; Lică I; Constantinescu G; Beuran M; Friess H
Rom J Intern Med; 2005; 43(3-4):173-85. PubMed ID: 16812978
[TBL] [Abstract][Full Text] [Related]
37. Cytokines and their relationship to the symptoms and outcome of cancer.
Seruga B; Zhang H; Bernstein LJ; Tannock IF
Nat Rev Cancer; 2008 Nov; 8(11):887-99. PubMed ID: 18846100
[TBL] [Abstract][Full Text] [Related]
38. Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention.
Moreira-Pais A; Ferreira R; Gil da Costa R
Life Sci; 2018 Sep; 208():1-9. PubMed ID: 30146014
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
Davis TW; Zweifel BS; O'Neal JM; Heuvelman DM; Abegg AL; Hendrich TO; Masferrer JL
J Pharmacol Exp Ther; 2004 Mar; 308(3):929-34. PubMed ID: 14711936
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of cancer cachexia.
Tisdale MJ
J Support Oncol; 2003; 1(3):159-68. PubMed ID: 15334872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
